4D Molecular Therapeutics Expands Phase 3 Trial Enrollment

4D Molecular Therapeutics ( (FDMT) ) has shared an update.

On December 10, 2025, 4D Molecular Therapeutics announced amendments to its Phase 3 clinical trials for 4D-150 in wet AMD, increasing target enrollment from 400 to 480 patients per trial. These changes are aimed at enhancing the trials’ power for global regulatory submissions and reflect the company’s evolving view of the commercial opportunity for 4D-150. The amendments are not expected to impact the company’s financial projections or enrollment timelines, with 4FRONT-1 and 4FRONT-2 trials continuing as planned, targeting completion in 2026 and topline data disclosure in 2027.

The most recent analyst rating on (FDMT) stock is a Hold with a $11.00 price target. To see the full list of analyst forecasts on 4D Molecular Therapeutics stock, see the FDMT Stock Forecast page.

Spark’s Take on FDMT Stock

According to Spark, TipRanks’ AI Analyst, FDMT is a Neutral.

4D Molecular Therapeutics shows potential due to positive corporate events and technical indicators, but financial performance and valuation remain challenging. The company’s ability to secure financing and strategic partnerships is a strong positive, but ongoing financial losses and negative cash flow present risks. The stock’s technical strength and strategic moves in the APAC market are key drivers of its score.

To see Spark’s full report on FDMT stock, click here.

More about 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc. operates in the biotechnology industry, focusing on developing genetic medicines. The company primarily works on therapies for ophthalmology, cardiology, and pulmonology, with a significant market focus on global regulatory submissions and partnerships, such as with Otsuka Pharmaceutical Co., Ltd.

Average Trading Volume: 843,012

Technical Sentiment Signal: Buy

Current Market Cap: $633.1M

See more insights into FDMT stock on TipRanks’ Stock Analysis page.